Yohimbine

Overview

Yohimbine (Yobine®, Antagonil®) is an alpha-2-adrenergic antagonist primarily used in veterinary medicine to reverse the sedative and cardiovascular effects of xylazine and other alpha-2 agonists in dogs and cats. It is most commonly administered following sedation or anesthesia to accelerate recovery and restore normal cardiovascular and neurologic function.

In small animal practice, yohimbine may also be used as part of the management of amitraz toxicosis, particularly when atipamezole is unavailable. Reversal effects are generally rapid after IV administration, although the duration of antagonism may be shorter than the duration of the alpha-2 agonist being reversed, resulting in possible recurrence of sedation.

Mechanism of Action (MOA): Yohimbine acts as a competitive alpha-2-adrenergic receptor antagonist, blocking both central and peripheral alpha-2 receptors. This increases sympathetic outflow and norepinephrine release, reversing sedation, bradycardia, and CNS depression induced by alpha-2 agonists such as xylazine. Yohimbine also produces CNS stimulation and may influence cardiovascular, gastrointestinal, and urinary functions.

At high doses, yohimbine may act as an AGONIST at alpha-1, dopamine, and serotonin receptors — a receptor-profile switch that helps explain the overdose picture (seizures, hyperthermia, hyperactivity).

Onset is about 3 minutes after IV administration in dogs when reversing xylazine; canine half-life is 1.5–2 h, volume of distribution 4.5 L/kg, and clearance 30 mL/min/kg. It penetrates the CNS readily.

Yohimbine HCl is a Rauwolfia (indolealkylamine) alkaloid chemically related to reserpine — a shared chemistry that helps explain the catastrophic reserpine-combination interaction (high doses of each have been uniformly fatal in dogs; see Drug Interactions).

Indications

Yohimbine is primarily used in dogs and cats as a reversal agent for xylazine and other alpha-2-adrenergic agonists. Its clinical use is focused on accelerating recovery from sedation or anesthesia and managing selected toxicities associated with alpha-2 agonist compounds.

• Reversal of xylazine sedation: Commonly used to reverse CNS depression, bradycardia, and prolonged sedation associated with xylazine administration in dogs and cats.
• Reversal of other alpha-2 agonists: May provide partial or complete reversal of the sedative and cardiovascular effects of certain alpha-2-adrenergic agonists when clinically indicated.
• Management of amitraz toxicity: Used as part of the treatment protocol for amitraz intoxication to counteract CNS depression, bradycardia, and other alpha-2-mediated toxic effects, particularly when atipamezole is unavailable.
• Adjunctive use before amitraz exposure: May be administered prophylactically prior to amitraz dips in selected patients to reduce the risk of systemic toxicity.
• Post-anesthetic recovery support: Used to shorten recovery time and restore normal physiologic function after alpha-2-containing anesthetic protocols.
• Atipamezole preferred in small animals (more selective): Atipamezole is more alpha-2-selective and is the PREFERRED reversal in small animals. Yohimbine is the older, less-selective alternative when atipamezole is unavailable.

Dosage (Reference)

Dog

In dogs, yohimbine is primarily administered intravenously for rapid reversal of xylazine sedation or as part of the management of amitraz toxicosis. Clinical response is usually rapid after IV administration, but monitoring is important because reversal effects may diminish before the agonist effects fully resolve.

Cat

In cats, yohimbine is primarily used as an extra-label reversal agent for xylazine-containing anesthetic or sedative protocols.

Warnings & Precautions

Yohimbine is a potent alpha-2-adrenergic antagonist that can rapidly reverse sedation and cardiovascular depression caused by xylazine and related agents. Because reversal may be abrupt, careful patient monitoring is recommended during and after administration.

• Seizure disorders: Use cautiously in patients with a history of seizures or conditions that lower the seizure threshold, as CNS stimulation and tremors may occur after administration.
• Renal disease: Use with caution in animals with renal impairment due to limited safety information and the potential for altered drug handling.
• Recurrence of sedation: The duration of yohimbine antagonism may be shorter than the duration of the alpha-2 agonist being reversed, leading to possible re-sedation after initial recovery.
• Return of pain perception: Reversal of alpha-2-mediated sedation may restore normal pain sensation rapidly; ensure adequate analgesia is provided when painful procedures or conditions are involved.
• Cardiovascular effects: Rapid sympathetic stimulation may cause tachycardia, hypertension, or excitement, particularly after IV administration or high doses.
• CNS excitation: Transient agitation, apprehension, vocalization, or hyperactivity may occur during recovery, especially in sensitive patients.
• IV administration: Administer intravenously slowly and with monitoring to reduce the risk of excessive cardiovascular or neurologic stimulation.
• Concurrent stimulants: Use cautiously with other drugs that can stimulate the CNS or sympathetic nervous system due to the risk of additive adverse effects.
• Patient monitoring: Monitor heart rate, blood pressure, respiratory status, and mentation closely after reversal, particularly in compromised or heavily sedated patients.
• Hypersensitivity contraindication: Hypersensitivity to yohimbine is an absolute contraindication. Prior allergic reaction = do not use.
• Pregnancy / lactation not established: Pregnancy / lactation safety has not been established. No lactation data. Use only if maternal benefit outweighs offspring risk.
• NOT for food-producing animals (US label): US label restriction: yohimbine is NOT for use in food-producing animals. Relevant in mixed and food-animal practice.
• ARCI Class 2 — racing withdrawal: ARCI Class 2 substance. Use of yohimbine may not be permitted in certain animal competitions; prolonged withdrawal periods may be required. Class 2 is more restrictive than xylazine’s Class 3.

Drug Interactions

Clinically significant interactions with yohimbine are primarily related to its alpha-2 antagonistic effects, sympathetic stimulation, and potential cardiovascular and CNS effects.

• Alpha-2 agonists (e.g., xylazine, medetomidine, dexmedetomidine): Yohimbine antagonizes the sedative, cardiovascular, and CNS effects of alpha-2 agonists and may rapidly reverse their clinical effects.
• Antihypertensive agents (e.g., ACE inhibitors, amlodipine, hydralazine): Yohimbine may reduce the effectiveness of antihypertensive medications through increased sympathetic tone and blood pressure elevation.
• Tricyclic antidepressants (e.g., amitriptyline, clomipramine): Concurrent use may increase the risk of hypertension, tachycardia, and excessive adrenergic stimulation.
• Reserpine: Concurrent administration may result in severe adverse cardiovascular effects; high-dose combinations have been associated with fatal reactions in dogs.
• Reserpine dose specifics — UNIFORMLY FATAL at 1 mg/kg each: Reserpine combination at 1 mg/kg IV of each was UNIFORMLY FATAL in dogs. Yohimbine is chemically related to reserpine (both Rauwolfia alkaloids), so the catastrophic interaction may reflect shared mechanism. AVOID this combination.
• Detomidine alters yohimbine PK: Detomidine (prior administration) decreases yohimbine clearance and increases peak plasma levels. Increases potential for adverse effects; reduce yohimbine dose accordingly when reversing detomidine.
• Concurrent CNS stimulants — additive risk: Watch for additive excitement, hyperactivity, hypertension when other CNS / sympathetic stimulants are on board . Review every co-medication before reversing.

Side Effects & Overdose

Side Effects

Adverse effects associated with yohimbine are generally related to rapid reversal of alpha-2 agonist effects and increased sympathetic stimulation. Most reactions are transient and dose-dependent.

• CNS excitement: Transient apprehension, agitation, hyperactivity, or excitability may occur during recovery.
• Muscle tremors: Trembling or mild muscle fasciculations may develop, particularly at higher doses.
• Tachycardia and hypertension: Increased sympathetic activity may result in elevated heart rate and blood pressure.
• Increased respiratory rate: Mild transient tachypnea may occur after reversal.
• Salivation: Hypersalivation has been reported in some patients following administration.
• Hyperemic mucous membranes: Peripheral vasomotor changes may cause reddened mucous membranes during recovery.
• Re-sedation: Sedation may recur if the duration of the alpha-2 agonist exceeds the duration of yohimbine antagonism.
• Antidiuretic effect: Yohimbine is antidiuretic — antagonises alpha-2-induced diuresis. A cat study showed it blocked xylazine- and medetomidine-driven urine production. Practical: less wet recovery.
• In vitro platelet aggregation inhibition: Platelet aggregation inhibition (in vitro) — an in vitro study found yohimbine inhibited collagen-induced platelet aggregation in vitro. Clinical significance in dogs / cats is unknown but worth noting in bleeding-risk patients.
• Increased GI sounds + antiemetic (cats): GI effects — yohimbine increases borborygmi / GI sounds and acts as an ANTIEMETIC in cats . Reduces post-sedation vomiting risk in cats.
• Yohimbine-alone pharmacology — hyperinsulinemia + biphasic BP: Yohimbine ALONE (no prior alpha-2 agonist) has two less-known pharmacologic actions: (1) HYPERINSULINEMIC effect — potential transient hypoglycaemia, especially in compromised or diabetic patients; (2) BP can DECREASE at HIGH doses (biphasic — the expected hypertension pattern can reverse). The insulin effect is supported by studies showing yohimbine reduced alpha-2-agonist-induced hyperglycaemia.

Overdose

Yohimbine overdose primarily results in excessive CNS and cardiovascular stimulation. Clinical signs are more likely with high doses or accidental ingestion of combination stimulant products containing yohimbine.

• Seizures and severe tremors: High doses may induce seizure activity, marked tremors, or severe CNS excitation.
• Marked tachycardia: Excessive sympathetic stimulation may cause significant increases in heart rate and cardiac workload.
• Hyperactivity and anxiety: Agitation, vocalization, restlessness, and behavioral excitement may occur.
•  5x-dose data — 0.55 mg/kg seizures + tremors: Specific overdose threshold — 0.55 mg/kg = 5× the recommended 0.11 mg/kg dose caused TRANSIENT seizures and muscle tremors. Useful triage data for unintentional overdose exposures.
• OTC stimulant combination overdose sign list: Presents with hyperactivity, tachycardia, anxiety, DIARRHEA, HIND-LIMB WEAKNESS, HYPERTHERMIA, INJECTED SCLERA, and vocalization. Look for these in dogs who got into owner’s OTC stimulant supplements.
• 24-h veterinary poison consultation: Call a 24-h veterinary poison control centre for any suspected yohimbine overdose — individualised supportive-care advice.

Key Notes

Practical clinical points that help optimize the safe and effective use of yohimbine in dogs and cats in everyday veterinary practice:

• Rapid reversal agent: Clinical improvement after IV administration is often rapid, making yohimbine useful when prolonged recovery from xylazine sedation is undesirable.
• Not a universal reversal drug: Yohimbine is most effective against xylazine and may provide incomplete reversal of some newer alpha-2 agonists.
• Improves recovery quality: Timely reversal may reduce prolonged recumbency, improve thermoregulation, and help patients regain normal physiologic function sooner.
• Useful in amitraz intoxication: Yohimbine remains a practical alternative when atipamezole is unavailable in the management of amitraz-associated toxicosis.
• Timing matters: Administration is commonly performed near the end of procedures to avoid premature arousal or sudden patient movement.
• Dose titration is important: Excessive doses may cause abrupt excitement or dysphoria rather than smooth recovery.
• Monitor recovery environment: Patients recovering after reversal should be kept in a quiet, controlled environment to reduce stress-related excitement.
• Analgesia planning: Reversal of sedation does not eliminate the need for ongoing pain management after procedures or toxicities.
• Titration pearl — start with 1/3 dose: Dose-titration pearl — start with ONE-THIRD of the recommended dose; repeat 1/3 at 5-10 minute increments if needed. The agonist effect may have already partially worn off when reversal is requested; a full dose can cause excitement instead of smooth wake-up.
• Onset 3 minutes IV : Onset is within 3 minutes IV when reversing xylazine. Plan recovery monitoring at the 3-minute mark.
• Atipamezole preferred in small animals: Atipamezole is the PREFERRED reversal in small animals — more alpha-2-selective and causes less excitement than yohimbine. Reserve yohimbine for cases where atipamezole isn’t available or affordable.
• FDA-approved DOGS ONLY (NADA# 140-866): Yobine 2 mg/mL is FDA-approved for DOGS ONLY (NADA# 140-866). All cat use is extra-label and should be documented in the chart with rationale.